Health Care

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

Hinge Health's Tech Is Primed To Capture America's Untapped MSK Pain Market: Analyst

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

Hinge Health's Tech Is Primed To Capture America's Untapped MSK Pain Market: Analyst

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Health Care Recent News

Surgery Partners Rejects Bain Capital's Private Buyout Offer, Will Remain Independent

Surgery Partners rejects Bain Capital's acquisition bid, citing greater long-term value as a public company with strong growth potential and strategic plans.

Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts

Fired vaccine experts warn that Health Secretary Robert F. Kennedy Jr.'s overhaul of the CDC's key vaccine advisory panel threatens public health and undermines decades of immunization progress, potentially impacting pharmaceutical companies and healthcare markets.

Amazon Overhauls Healthcare Business To Streamline Structure As Exec Officers Leave

Amazon restructures its health division, adds leadership, and expands pharmacy access with same-day delivery to nearly half of U.S. customers.

Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access without insurance barriers.

T. Rowe Price Expands ETF Lineup With 3 Actively Managed Sector Picks Across Key Sectors

T. Rowe Price launches 3 new actively managed ETFs with lower costs, providing diversified, research-based access to high-impact industries.

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst

Intuitive Surgical remains in focus as analysts weigh reprocessing risks after Restore Robotics secures FDA clearance for remanufactured tools.

Trump's Tax Plan Could Leave Millions Uninsured, Hit Rural America Hard

Trump's proposed tax and spending bill could slash $785 billion from Medicaid, threatening rural hospitals and potentially leaving 11 million more Americans uninsured.

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

Medtronic Is Separating Its Diabetes Business - Good News For Investors

AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion

AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.